Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab vs cyclophosphamide in idiopathic refractory scleritis
2017-004969-27Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in idiopathic scleritis, Anterior idiopathic scleritis and scleritis comparing Infliximab + low-dose methotrexate with Cyclophosphamide (2 arms). Started Apr 2018; status: completed.
02
Drugs
infliximabcyclophosphamide
03
Conditions
idiopathic scleritisAnterior idiopathic scleritisscleritis
Beyond the preview
Go deeper on 2017-004969-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004969-27.